北京大学学报(医学版) ›› 2024, Vol. 56 ›› Issue (5): 928-931. doi: 10.19723/j.issn.1671-167X.2024.05.028
Dongwu LIU1, Jie CHEN2, Mingli GAO1, Jing YU1,*()
中图分类号:
1 |
Demirkan FG , Doǧan S , Kalyoncu Uçar A , et al. Systemic lupus erythematosus complicated with Castleman disease: A case-based review[J]. Rheumatol Int, 2021, 41 (2): 475- 479.
doi: 10.1007/s00296-020-04684-4 |
2 |
Minemura H , Tanino Y , Ikeda K . Possible association of multicentric Castleman' s disease with autoimmune lymphoproliferative syndrome[J]. Biores Open Access, 2018, 7 (1): 47- 51.
doi: 10.1089/biores.2017.0025 |
3 |
Tabata S , Higuchi T , Tatsukawa S , et al. Idiopathic multicentric Castleman disease with autoimmune hemolytic anemia and production of anti-drug antibody against tocilizumab[J]. Intern Med, 2019, 58 (22): 3313- 3318.
doi: 10.2169/internalmedicine.2989-19 |
4 | 中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42 (7): 529- 534. |
5 | 郑东辉, 莫颖倩, 戴冽, 等. 类风湿关节炎不同滑膜淋巴细胞分布类型的临床病理特点[J]. 中山大学学报(医学科学版), 2009, 30 (5): 571- 576. |
6 | 张玲玲, 魏伟. BAFF/BAFF-R通过PI3K/Akt/mTOR信号转导通路调节B淋巴细胞功能在类风湿关节炎发病机制中的意义[J]. 中国药理学通报, 2010, 26 (7): 847- 850. |
7 | Picemo V , Ferro F , Adinolfi A , et al. One year in riview: The pathogenesis of rheumatoid arthritis[J]. Clin Exp Rheumatol, 2015, 33 (4): 551- 558. |
8 | 唐果, 龙丽, 韩雅欣, 等. 类风湿关节炎合并结核感染的临床特点及相关因素[J]. 北京大学学报(医学版), 2020, 52 (6): 1029- 1033. |
9 | 刘娣, 郭万珍, 蔡华聪, 等. 类风湿关节炎并发淋巴瘤的临床特征[J]. 中华临床免疫和变态反应杂志, 2015, 9 (4): 292- 296. |
10 |
Castleman B , Towne V . Case records of the Massachusetts General Hospital weekly clinicopathological exercises: Case 40011[J]. N Engl J Med, 1954, 250 (1): 26- 30.
doi: 10.1056/NEJM195401072500107 |
11 |
Wang HW , Pittaluga S , Jaffe ES . Multicentric Castleman disease: Where are we now?[J]. Semin Diagn Pathol, 2016, 33 (5): 294- 306.
doi: 10.1053/j.semdp.2016.05.006 |
12 |
Nguyen D , Diamond L , Hansmann N , et al. Castleman' s disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants[J]. Histopathology, 1994, 24 (5): 437- 443.
doi: 10.1111/j.1365-2559.1994.tb00552.x |
13 |
Herrada J , Cabanillas F , Rice L , et al. The clinical behavior of localized and multicentric Castleman disease[J]. Ann Intern Med, 1998, 128 (8): 657- 662.
doi: 10.7326/0003-4819-128-8-199804150-00010 |
14 | Peterson B , Frizzera G . Multicentric Castleman' s disease[J]. Semin Oncol, 1993, 20 (6): 636- 647. |
15 |
Frizzera G , Peterson BA , Bayrd ED , et al. A systemic lymphoproliferative disorder with morphologic features of Castleman' s disease: Clinical findings and clinicopathologic correlations in 15 patients[J]. J Clin Oncol, 1985, 3 (9): 1202- 1216.
doi: 10.1200/JCO.1985.3.9.1202 |
16 |
Bowne WB , Lewis JJ , Filippa DA , et al. The management of unicentric and multicentric Castleman' s disease: A report of 16 cases and a review of the literature[J]. Cancer, 1999, 85 (3): 706- 717.
doi: 10.1002/(SICI)1097-0142(19990201)85:3<706::AID-CNCR21>3.0.CO;2-7 |
17 |
Nishimoto N , Kanakura Y , Aozasa K , et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease[J]. Blood, 2005, 106 (8): 2627- 2632.
doi: 10.1182/blood-2004-12-4602 |
18 |
Casper C , Voorhees PM , Fayad LE , et al. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman' s disease[J]. Blood, 2013, 122 (21): 1806.
doi: 10.1182/blood.V122.21.1806.1806 |
19 | de Marchi G , de Vita S , Fabris M , et al. Systemic connective tissue disease complicated by Castleman' s disease: Report of a case and review of the literature[J]. Haematologica, 2004, 89 (4): 7- 10. |
20 |
Jacobs SA , Vidnovic N , Patel H , et al. Durable remission of HIV-negative, Kaposi' s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate[J]. Clin Rheumatol, 2007, 26 (7): 1148- 1150.
doi: 10.1007/s10067-006-0272-8 |
21 | Sun Y , Wang D , Salvadore G , et al. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castle-man' s disease[J]. Brain Behav Immun, 2017, 66 (11): 156- 164. |
[1] | 黄会娜,赵静,赵祥格,白自然,李霞,王冠. 乳酸对类风湿关节炎患者外周血CD4+T细胞亚群的调控作用[J]. 北京大学学报(医学版), 2024, 56(3): 519-525. |
[2] | 汤晓菲,李永红,丁秋玲,孙卓,张阳,王育梅,田美伊,刘坚. 类风湿关节炎患者下肢深静脉血栓发病率及危险因素[J]. 北京大学学报(医学版), 2024, 56(2): 279-283. |
[3] | 邹雪,白小娟,张丽卿. 艾拉莫德联合托法替布治疗难治性中重度类风湿关节炎的疗效[J]. 北京大学学报(医学版), 2023, 55(6): 1013-1021. |
[4] | 吴琦,蔡月明,何娟,黄文蒂,王庆文. 血脂异常与类风湿关节炎肺间质病变的相关性分析[J]. 北京大学学报(医学版), 2023, 55(6): 982-992. |
[5] | 张警丰,金银姬,魏慧,姚中强,赵金霞. 体重指数与类风湿关节炎临床特征的相关性分析[J]. 北京大学学报(医学版), 2023, 55(6): 993-999. |
[6] | 金银姬,孙琳,赵金霞,刘湘源. 血清IgA型抗鼠科肉瘤病毒癌基因同源物B1抗体在类风湿关节炎中的意义[J]. 北京大学学报(医学版), 2023, 55(4): 631-635. |
[7] | 蔡文心,李仕成,刘一鸣,梁如玉,李静,郭建萍,胡凡磊,孙晓麟,李春,刘栩,叶华,邓立宗,李茹,栗占国. 类风湿关节炎临床分层及其特征的横断面研究[J]. 北京大学学报(医学版), 2022, 54(6): 1068-1073. |
[8] | 程昉,杨邵英,房星星,王璇,赵福涛. CCL28-CCR10通路在类风湿关节炎单核细胞迁移中的作用[J]. 北京大学学报(医学版), 2022, 54(6): 1074-1078. |
[9] | 刘蕊,赵金霞,闫良. 类风湿关节炎合并下肢静脉血栓患者的临床特点[J]. 北京大学学报(医学版), 2022, 54(6): 1079-1085. |
[10] | 张警丰,金银姬,魏慧,姚中强,赵金霞. 类风湿关节炎患者生活质量与疾病活动度的横断面研究[J]. 北京大学学报(医学版), 2022, 54(6): 1086-1093. |
[11] | 高超,陈立红,王莉,姚鸿,黄晓玮,贾语博,刘田. 类风湿关节炎合并纤维肌痛简易分类标准的临床验证[J]. 北京大学学报(医学版), 2022, 54(2): 278-282. |
[12] | 娄雪,廖莉,李兴珺,王楠,刘爽,崔若玫,徐健. 类风湿关节炎患者外周血TWEAK基因启动子区甲基化状态及其表达[J]. 北京大学学报(医学版), 2021, 53(6): 1020-1025. |
[13] | 钟华,徐丽玲,白明欣,苏茵. 类风湿关节炎患者趋化因子CXCL9和CXCL10在骨侵蚀中的作用[J]. 北京大学学报(医学版), 2021, 53(6): 1026-1031. |
[14] | 罗靓,霍文岗,张钦,李春. 类风湿关节炎合并角膜溃疡的临床特点和相关因素分析[J]. 北京大学学报(医学版), 2021, 53(6): 1032-1036. |
[15] | 张璐,胡小红,陈澄,蔡月明,王庆文,赵金霞. 类风湿关节炎初治患者颈椎失稳情况及临床特征[J]. 北京大学学报(医学版), 2021, 53(6): 1049-1054. |
|